| Style | Citing Format |
|---|---|
| MLA | Etemadifar M, et al.. "Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series." Brain Disorders, vol. 24, no. , 2026, pp. -. |
| APA | Etemadifar M, Teimouri K, Rezaei M, Salari M, Ebne Ali Heydari Y, Norouzi M (2026). Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series. Brain Disorders, 24(), -. |
| Chicago | Etemadifar M, Teimouri K, Rezaei M, Salari M, Ebne Ali Heydari Y, Norouzi M. "Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series." Brain Disorders 24, no. (2026): -. |
| Harvard | Etemadifar M et al. (2026) 'Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series', Brain Disorders, 24(), pp. -. |
| Vancouver | Etemadifar M, Teimouri K, Rezaei M, Salari M, Ebne Ali Heydari Y, Norouzi M. Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series. Brain Disorders. 2026;24():-. |
| BibTex | @article{ author = {Etemadifar M and Teimouri K and Rezaei M and Salari M and Ebne Ali Heydari Y and Norouzi M}, title = {Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series}, journal = {Brain Disorders}, volume = {24}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Etemadifar M AU - Teimouri K AU - Rezaei M AU - Salari M AU - Ebne Ali Heydari Y AU - Norouzi M TI - Safety and Efficacy of Continuous Dimethyl Fumarate Treatment During Conception, Pregnancy, and Lactation in Females With Multiple Sclerosis: A Case Series JO - Brain Disorders VL - 24 IS - SP - EP - PY - 2026 ER - |